title: Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life.
abstract: The aim of this study was to assess the effects of intravenous co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin during the first days of life in preterm infants. The pharmacokinetics of amikacin were retrospectively calculated in a cohort of 73 neonates (gestational age <31 weeks) who received either ibuprofen-lysine or placebo following inclusion in the multicentre ibuprofen prophylaxis study. Assuming a one-compartment model with instantaneous input and first-order output, there was no significant difference in the median distribution volume (0.63 vs. 0.59 liters/kg), but the median serum half-life (16.4 vs. 12.4 h) of amikacin was significantly longer (p <0.02), and the clearance (0.36 vs. 0.6 ml/kg/min; p <0.005) of amikacin was significantly lower in infants who received ibuprofen-lysine. We conclude that the time interval between consecutive amikacin administrations should be prolonged, if ibuprofen-lysine is co-administered.
authors.affiliation: Neonatal Intensive Care Unit, University Hospital Gasthuisberg, Leuven, Belgium. karel.allegaert@uz.kuleuven.ac.be
authors.forename: K
authors.initials: K
authors.lastname: Allegaert
authors.forename: V
authors.initials: V
authors.lastname: Cossey
authors.forename: J P
authors.initials: JP
authors.lastname: Langhendries
authors.forename: G
authors.initials: G
authors.lastname: Naulaers
authors.forename: C
authors.initials: C
authors.lastname: Vanhole
authors.forename: H
authors.initials: H
authors.lastname: Devlieger
authors.forename: B
authors.initials: B
authors.lastname: Van Overmeire
mesh_terms: D000583:Amikacin / Q000493:pharmacokinetics*; D001424:Bacterial Infections / Q000517:prevention & control; D004311:Double-Blind Method; D005865:Gestational Age; D006207:Half-Life; D006801:Humans; D007052:Ibuprofen / Q000008:administration & dosage*; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000517:prevention & control; D007262:Infusions, Intravenous; D008239:Lysine / Q000008:administration & dosage*; D008657:Metabolic Clearance Rate; D010919:Placebos; D012189:Retrospective Studies
chemical_list: D010919:Placebos; D000583:Amikacin; D008239:Lysine; D007052:Ibuprofen